Brett P. Monia - 06 Feb 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
Chief Executive Officer, Director
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia
Issuer symbol
IONS
Transactions as of
06 Feb 2026
Net transactions value
-$2,524,820
Form type
4
Filing time
10 Feb 2026, 17:04:29 UTC
Previous filing
02 Feb 2026
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Monia Brett P Chief Executive Officer, Director 2855 GAZELLE COURT, CARLSBAD By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia 09 Feb 2026 0001537529

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Sale $2,524,820 -29,430 -10% $85.79 254,497 06 Feb 2026 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 13, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.22 to $86.055 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.